MEDNAX (NYSE:MD) has been assigned a $55.00 target price by analysts at SunTrust Banks in a research report issued to clients and investors on Thursday. The firm currently has a “hold” rating on the stock. SunTrust Banks’ target price would indicate a potential upside of 4.70% from the stock’s previous close.

MD has been the topic of a number of other reports. Robert W. Baird reissued a “hold” rating and issued a $47.00 price objective on shares of MEDNAX in a report on Sunday, September 3rd. Zacks Investment Research raised MEDNAX from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Piper Jaffray Companies assumed coverage on MEDNAX in a report on Wednesday, December 13th. They issued an “overweight” rating and a $58.00 price objective on the stock. KeyCorp set a $51.00 price objective on MEDNAX and gave the company a “buy” rating in a report on Wednesday, November 1st. Finally, BMO Capital Markets assumed coverage on MEDNAX in a report on Monday, October 16th. They issued a “market perform” rating and a $46.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $53.82.

Shares of MEDNAX (NYSE:MD) opened at $52.53 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. MEDNAX has a 12 month low of $40.56 and a 12 month high of $72.13. The company has a market capitalization of $4,844.79, a PE ratio of 15.82, a price-to-earnings-growth ratio of 1.67 and a beta of 0.40.

MEDNAX (NYSE:MD) last released its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, meeting analysts’ consensus estimates of $0.87. MEDNAX had a return on equity of 10.80% and a net margin of 7.76%. The company had revenue of $868.95 million during the quarter, compared to analysts’ expectations of $864.78 million. During the same period last year, the business posted $1.09 earnings per share. The firm’s revenue was up 4.9% compared to the same quarter last year. equities research analysts predict that MEDNAX will post 3.1 EPS for the current year.

In other MEDNAX news, Director Cesar L. Alvarez sold 10,668 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the sale, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares in the company, valued at $1,834,649.02. The disclosure for this sale can be found here. 2.40% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its holdings in MEDNAX by 0.3% in the second quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock valued at $498,505,000 after purchasing an additional 28,155 shares during the period. Vanguard Group Inc. grew its holdings in MEDNAX by 0.5% in the second quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after purchasing an additional 38,645 shares during the period. Thompson Siegel & Walmsley LLC grew its holdings in MEDNAX by 19.7% in the third quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock valued at $112,065,000 after purchasing an additional 428,184 shares during the period. Nordea Investment Management AB grew its holdings in MEDNAX by 4.8% in the third quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock valued at $100,198,000 after purchasing an additional 106,883 shares during the period. Finally, Earnest Partners LLC grew its holdings in MEDNAX by 0.7% in the third quarter. Earnest Partners LLC now owns 1,494,374 shares of the company’s stock valued at $64,437,000 after purchasing an additional 11,037 shares during the period. 98.43% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.dailypolitical.com/2017/12/22/mednax-md-given-a-55-00-price-target-at-suntrust-banks.html.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.